Growth & profitability
- Revenue has declined 14.2% per year over the past 5 years.
Financial health
- The company is unprofitable and has less than a year of cash runway at its current free-cash-flow burn.
PYXS Financials Pyxis Oncology, Inc.
6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $14M | -$80M | 82.8% | -609.2% | -$64M | — | $15M |
| 2024 | $16M | -$77M | 97.1% | -554.1% | -$58M | — | $19M |
| 2023 | — | -$74M | — | — | -$77M | — | $10M |
| 2022 | — | -$121M | — | — | -$96M | — | $179M |
| 2021 | — | -$76M | — | — | -$36M | — | $275M |
| 2020 | — | -$13M | — | — | -$12M | — | $8M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$23M | — | — | — | — | $6M |
| Dec '25 | $11M | -$18M | 0.0% | -165.7% | -$10M | — | $15M |
| Sep '25 | $0 | -$22M | — | — | — | — | $9M |
| Jun '25 | $3M | -$18M | 0.0% | -700.4% | — | — | $11M |
| Mar '25 | — | -$21M | — | — | — | — | $13M |
| Dec '24 | $0 | -$36M | — | — | -$19M | — | $19M |
| Sep '24 | $0 | -$21M | — | — | -$15M | — | $12M |
| Jun '24 | $0 | -$17M | — | — | -$3M | — | $25M |
| Mar '24 | $16M | -$3M | 97.1% | -34.7% | -$21M | — | $28M |
| Dec '23 | — | -$16M | — | — | -$15M | — | $10M |
| Sep '23 | — | -$23M | — | — | -$18M | — | $15M |
| Jun '23 | — | -$16M | — | — | -$13M | — | $26M |
| Mar '23 | — | -$19M | — | — | -$31M | — | $53M |
| Dec '22 | — | -$36M | — | — | -$19M | — | $179M |
| Sep '22 | — | -$28M | — | — | -$25M | — | $199M |
| Jun '22 | — | -$26M | — | — | -$24M | — | $223M |
| Mar '22 | — | -$31M | — | — | -$28M | — | $247M |
| Dec '21 | — | -$17M | — | — | -$12M | — | $275M |
| Sep '21 | — | -$14M | — | — | -$7M | — | $133M |
| Jun '21 | — | -$8M | — | — | $2M | — | $142M |
Valuation over time
How the market has priced PYXS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 6.2× (Dec '24) to 10.2× (Jun '26).
P/S
Frequently asked questions
Is PYXS growing its revenue and profit?
Over the past 5 years, Pyxis Oncology, Inc.'s revenue has declined 14.2% per year. These are computed facts, not advice.
How much debt does PYXS have?
As of FY2025, Pyxis Oncology, Inc. reported — of total debt against $15M of cash.
What is PYXS's profit margin?
In FY2025, gross margin was 82.8%, operating margin -609.2%, and net margin -574.5%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.